prostate cancer

Prostate Ca: Novel model predicts ‘true cancer state’Although various calculators are available for predicting biopsy results in men with prostate cancer being managed by active surveillance, a novel model developed by researchers at Johns Hopkins University is unique for its ability to predict a patient’s “true cancer state”; ie, the Gleason score that would be assigned on whole-gland analysis after radical prostatectomy.
Slow breathing technique helps reduce hot flashesA slow breathing technique guided by an iOS application was able to reduce the occurrence of vasomotor symptoms in a small study of prostate cancer survivors treated with androgen deprivation therapy.
QoL prognostic in mCRPC patients on salvage therapyClinical outcomes of men with metastatic castration-resistant prostate cancer treated with enzalutamide (XTANDI) after chemotherapy correlate with health-related quality of life both at treatment initiation and its change longitudinally, researchers reported at the American Society of Clinical Oncology annual meeting in Chicago.
Negative mpMRI does not rule out significant PCaAs interest in using multiparametric MRI as a diagnostic tool for prostate cancer increases, urologists should know that a negative mpMRI does not rule out significant prostate cancer, researchers advised at the AUA annual meeting in San Diego.
Uro Pipeline: Bladder Ca drug-device combination begins second phase Ib trialA bladder cancer drug-device combination, a localized prostate cancer agent, and a new surgical robot are among other treatments in the pipeline discussed in this round-up.
Prostate Ca: Are more men presenting with metastatic disease?A study reporting an increase in the number of men initially presenting with metastatic prostate cancer has been the source of controversy since its July publication.
Robotic vs. open RP: Experts react to first randomized trialWe spoke to Gerald L. Andriole, MD, Michael Koch, MD, Herbert Lepor, MD, Mani Menon, MD, and Joel Nelson, MD, about the highly anticipated study findings.
Study: PCa genomic test reduces decisional conflictFor men with high-risk pathology at radical prostatectomy, exposure to results of a genomic test that classifies 5-year risk of metastasis reduces decisional conflict, according to findings of a prospective study presented at the American Society of Clinical Oncology annual meeting in Chicago.
Wellness in urology: Consider non-drug measures up frontIn this interview, Mark A. Moyad, MD, MPH, discusses non-drug interventions for urologic conditions, the difference between prescription drugs and nutraceuticals, and why a heart-healthy diet is a prostate-healthy diet.
Cognitive, mood effects characterized for PCa therapiesAn ongoing phase II trial investigating abiraterone acetate (ZYTIGA) and enzalutamide (XTANDI) as treatment for men with chemotherapy-naïve metastatic castrate-resistant prostate cancer is aiming to characterize the effects of these targeted hormonal therapies on cognition and mood.